Presentations to be Webcast on Feb. 15 and February 22
WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 6, 2017--
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that Jay R. Luly, Ph.D., President and Chief Executive Officer, will
present at each of the following investor conferences:
February 15, 2:30 p.m. ET – LEERINK Partners 6th Annual
Global Healthcare Conference, New York
February 22, 2:35 p.m. ET – RBC Capital Markets 2017 Global Healthcare
Conference, New York
A live webcast and replay of each presentation will be accessible by
visiting the “Calendar of Events” section on the “Investors” page of
Enanta’s website at www.enanta.com.
The webcast replay will be available following each presentation and
will be archived for approximately 30 days.
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs for viral
infections and liver diseases. Enanta’s research and development efforts
are currently focused on the following disease targets: non-alcoholic
steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory
syncytial virus (RSV) and hepatitis B virus (HBV).
Enanta has discovered novel protease inhibitors for use against the
hepatitis C virus (HCV). These protease inhibitors, developed through
Enanta’s collaboration with AbbVie, include paritaprevir, currently
marketed in AbbVie’s HCV regimens, and glecaprevir (ABT-493), Enanta’s
second protease inhibitor product, which AbbVie is developing as part of
its investigational HCV regimen of glecaprevir/pibrentasvir (G/P)
currently under regulatory review in the U.S. and the E.U. Royalties and
any further milestone payments from this collaboration will provide
funding for Enanta’s earlier development programs, including its Phase 1
FXR agonist program for NASH/PBC, and its preclinical programs for HBV
and RSV. Please visit www.enanta.com
for more information on Enanta’s programs and pipeline.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170206005725/en/
Source: Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc.
MacDougall Biomedical Communications